North Dakota 2023-2024 Regular Session

North Dakota Senate Bill SB2140

Introduced
1/3/23  
Refer
1/3/23  
Report DNP
2/7/23  
Refer
2/8/23  
Report Pass
2/13/23  
Engrossed
2/15/23  
Refer
2/17/23  
Report Pass
3/27/23  
Refer
3/27/23  
Report Pass
4/3/23  
Enrolled
4/12/23  

Caption

Self-insurance health plans; to provide for a report; to provide for application; and to provide an expiration date.

Impact

The bill seeks to enact a critical shift in how health insurance operates for public employees in North Dakota, particularly in the context of diabetes management. By placing a cap on out-of-pocket costs for insulin and its associated supplies, SB2140 may contribute to reducing financial barriers for individuals relying on these critical medications and supplies. Moreover, the legislation could set a precedent for insurance coverage practices within the state, potentially influencing future healthcare-related policies and legislation.

Summary

Senate Bill No. 2140 aims to provide substantive amendments to the public employees retirement system health benefits coverage concerning insulin drugs and medical supplies. The bill specifies limitations on out-of-pocket expenses for insulin and related supplies, ensuring that individuals will only pay up to $25 for a thirty-day supply of covered insulin drugs and medical supplies necessary for insulin administration. This initiative addresses concerns related to the accessibility and affordability of essential diabetes management supplies for public employees in North Dakota.

Sentiment

General sentiment around SB2140 appears to be largely supportive, especially among public health advocates and organizations focused on diabetes care. The bill is seen as a significant step towards ensuring that individuals with diabetes can manage their condition without facing exorbitant costs. However, there are also concerns raised by some members regarding the sustainability of implementing such coverage limits and ensuring that they do not negatively impact insurance providers' financial stability.

Contention

Despite the overall positive reception of the bill, notable points of contention include ongoing debates about the expiration date of the coverage provisions set for July 31, 2025. Many stakeholders express concerns that this temporary nature may lead to uncertainty regarding the future of insulin affordability in North Dakota. Additionally, discussions about the distinction between necessary supplies for diabetes management and those excluded from coverage, such as insulin pumps and continuous glucose monitors, further complicate the discourse around the bill.

Companion Bills

No companion bills found.

Similar Bills

No similar bills found.